Imagine being able to predict which epilepsy patients might face a tougher battle with seizures, even before their condition becomes severe. That's the groundbreaking potential of a new study unveiled at the 2025 American Epilepsy Society (AES) Annual Meeting. Researchers have uncovered specific EEG and MRI markers in patients with Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) and epilepsy, offering a glimpse into a future where early intervention could transform treatment outcomes. But here's where it gets controversial: could these biomarkers not only predict severity but also challenge our current understanding of epilepsy management? Let’s dive in.
The study, led by Ally Byrd from Ann & Robert H. Lurie Children’s Hospital in Chicago, analyzed 49 MOGAD-positive patients admitted between 2015 and 2025. Among them, 14 experienced seizures, with half presenting seizures as their first symptom and 28% developing status epilepticus—a life-threatening condition of prolonged seizures. MOGAD, a central nervous system disorder, often overlaps with conditions like multiple sclerosis and neuromyelitis optica spectrum disorder, making epilepsy one of its complex manifestations.
And this is the part most people miss: One-third of patients showed normal EEGs and didn’t require long-term anti-seizure medication, while another third developed refractory epilepsy—a form resistant to typical treatments. Strikingly, all patients with intractable epilepsy exhibited focal slowing and interictal epileptiform discharges, primarily in the temporal lobe. MRI scans revealed cortical lesions in the frontal and temporal lobes, deep gray matter involvement, and abnormalities like FLAIR hyperintensities and ring-enhancing lesions. In contrast, patients without epilepsy often presented with optic neuritis or transverse myelitis.
Here’s where it gets intriguing: MOG antibody titers were significantly higher in patients with epilepsy (median 1:1,000) compared to those without (mean 1:160). This aligns with recent research linking elevated MOG titers to relapsing disease and severe phenotypes like cortical encephalitis, which carry higher seizure risks. But could this mean that managing MOGAD more aggressively early on could prevent epilepsy from becoming refractory? It’s a question that sparks debate.
The researchers concluded that higher MOG titers and specific EEG/MRI abnormalities could serve as early biomarkers for refractory epilepsy. Early detection of these markers might allow for timely immunotherapy, potentially improving long-term seizure control and neurological outcomes. However, this raises a thought-provoking question: Are we ready to shift our treatment paradigms based on these biomarkers, or do we need more research to validate their predictive power?
What do you think? Should these findings prompt immediate changes in how we approach MOGAD-related epilepsy, or is it too early to draw definitive conclusions? Share your thoughts in the comments below. For more insights from AES 2025, click here: AES 2025 Coverage.
References:
1. Younis L, Tatachar P, Thakkar K, et al. EEG and MRI Biomarkers in MOGAD Patients with Epilepsy. Presented at: 2025 AES Annual Meeting; December 5-9; Atlanta, GA. ABSTRACT 2.247.
2. Sapana T, Zhuo Z. Biomarkers for MOGAD Diagnosis and Prognosis. Multiple Sclerosis & Neuroimmun. 2025;16. doi:10.3389/fimmu.2025.1594960.
Stay ahead in neurology—subscribe to NeurologyLive for expert insights, cutting-edge data, and treatment breakthroughs.
